Literature DB >> 25091612

Skin cancer: less is as good as more in refractory melanoma.

Lisa Hutchinson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25091612     DOI： 10.1038/nrclinonc.2014.132

Source DB:  PubMed          Journal:  Nat Rev Clin Oncol        ISSN： 1759-4774            Impact factor:   66.675


× No keyword cloud information.
  1 in total

1.  Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial.

Authors:  Caroline Robert; Antoni Ribas; Jedd D Wolchok; F Stephen Hodi; Omid Hamid; Richard Kefford; Jeffrey S Weber; Anthony M Joshua; Wen-Jen Hwu; Tara C Gangadhar; Amita Patnaik; Roxana Dronca; Hassane Zarour; Richard W Joseph; Peter Boasberg; Bartosz Chmielowski; Christine Mateus; Michael A Postow; Kevin Gergich; Jeroen Elassaiss-Schaap; Xiaoyun Nicole Li; Robert Iannone; Scot W Ebbinghaus; S Peter Kang; Adil Daud
Journal:  Lancet       Date:  2014-07-15       Impact factor: 79.321
  1 in total
  2 in total

1.  VS-5584, a Novel PI3K-mTOR Dual Inhibitor, Inhibits Melanoma Cell Growth In Vitro and In Vivo.

Authors:  Zheren Shao; Qi Bao; Fangzhen Jiang; Huan Qian; Quan Fang; Xueqing Hu
Journal:  PLoS One       Date:  2015-07-23       Impact factor: 3.240

2.  Liposomal C6 Ceramide Activates Protein Phosphatase 1 to Inhibit Melanoma Cells.

Authors:  Fangzhen Jiang; Kai Jin; Shenyu Huang; Qi Bao; Zheren Shao; Xueqing Hu; Juan Ye
Journal:  PLoS One       Date:  2016-09-15       Impact factor: 3.240
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.